Effects of live trigeminal bifidobacterium, lactobacillus and enterococcus powder on the recurrence of wheezing in atopic children with bronchiolitis
10.3969/j.issn.1009-0754.2016.02.008
- VernacularTitle:双歧杆菌三联活菌散对特应性体质患儿毛细支气管炎后再发喘息的预防作用
- Author:
Mingxing REN
1
;
Guochang XUE
;
Linna SHEN
;
Liwen ZHANG
;
Yuejuan SONG
;
Huan XIA
;
Xuexia XIA
Author Information
1. 苏州大学附属无锡市第九人民医院儿科
- Keywords:
Bronchiolitis;
Live trigeminal bifidobacterium,lactobacillus and enterococcus powder;
Eosinophil;
Transforming growth factor-beta 1
- From:
Journal of Navy Medicine
2016;37(2):118-120,146
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the effects of live trigeminal bifidobacterium, lactobacillus and enterococcus powder on the recurrence of wheezing, and the levels of peripheral blood eosinophil ( EOS) and serum transforming growth factor-beta 1( TGF-β1) in atopic children with bronchiolitis.Methods Sixty atopic children with bronchiolitis were randomly divided into the therapy group (30 cases) and the conventional treatment group (30 cases) and another 25 healthy children were recruited as the healthy control group. The conventional treatment group was given routine therapy, and the therapy group received live trigeminal bifidobacterium, lactobacil-lus and enterococcus, in addition to routine therapy for 2 months.The levels of EOS and TGF-β1 were detected at the acute stage and 2 months after receiving trigeminal bifidobacterium, lactobacillus and enterococcus.Results (1) The recurrent rate of wheezing after medication for the therapy group (0.67 ±0.13) was significantly lower than that for the conventional treatment group (1.27 ±0.17), with statistical significance (P<0.05).(2)The levels of EOS of the therapy group [(0.72 ±0.13) ×109/L] and the conventional treatment group [(0.70 ±0.13) ×109/L] at the acute stage were markedly higher than those of the healthy control group [(0.16 ± 0.09) ×109/L], also with statistical significance (P<0.05).The levels of TGF-β1 of the therapy group [(1.20 ±0.13) ng/L] and the conventional treatment group(1.22 ±0.11) at acute stage were all considerably lower than those of the control group [(1.45 ± 0.13) ng/L], with statistical significance (P<0.05).The level of EOS in the therapy group [(0.27 ±0.12) ×109/L] 2 months af-ter medication of oral live trigeminal bifidobacterium, lactobacillus and enterococcus powder was lower than that in the conventional treatment group [(0.36 ±0.14) ×109/L], also with statistical significance (P<0.05).The level of TGF-β1 of the therapy group [(1.41 ±0.09) ng/L] 2 months after medication was markedly higher than that of the conventional treatment group [(1.34 ±0.10) ng/L], also with statistical significance (P<0.05).Conclusion Oral medication of live trigeminal bifidobacterium, lactobacillus and enterococcus powder for 2 months could obviously reduce the recurrent rate of wheezing within 6 months after the onset of bronchiolitis and could also up-regulate the levels of EOS and TGF-β1 in atopic children with bronchiolitis.
